Dyne Therapeutics, Inc. (DYN)

Market Cap	621.87M
Revenue (ttm)	n/a
Net Income (ttm)	-181.06M
Shares Out	51.80M
EPS (ttm)	-3.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	166,058
Open	11.87
Previous Close	11.93
Day's Range	11.52 - 12.18
52-Week Range	4.3 - 15.63
Beta	0.05
Analysts	Buy
Price Target	25.50 (+114.3%)
Earnings Date	Nov 3, 2022

About DYN

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..

• Industry: Independent Power and Renewable Electricity Producers
• IPO Date: Sep 17, 2020
• Employees: 115
• Stock Exchange: NASDAQ
• Ticker Symbol: DYN

Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for DYN stock is "Buy." The 12-month stock price forecast is 25.5, which is an increase of 114.29% from the latest price.

Price Target

$25.5

(114.29% upside)

Analyst Consensus: Buy

Stock Forecasts